effect of berberine on testosterone secretion from...
TRANSCRIPT
1
Effect of Berberine on Testosterone secretion from
Testicular TM3 cell lines in hypoxia condition.
Yi – Jing Chen1, Ju-Wen Yu
1, Hea-Wen Tzou
1, Yuan-Hao Chang
1, Ya-Wen Jeng
2 and
Shyi-Wu Wang2*
1Graduate Institute of Biomedical Sciences,
2Department of Physiology and
Pharmacology, College of Medicine, Chang-Gung University, Kweisan,
Taoyuan, Taiwan, ROC
Key words: hypoxia, berberine, Leydig TM3 cells, testosterone
*Correspondence : Shyi-Wu Wang, Ph. D.
Department of Physiology and Pharmacology
Chang Gung University
Taoyuan 33333, Taiwan,
Republic of China.
Tel No.: 886-3-211-8800 EXT 5253
Fax No.: 886-3-3288448
2
Abstract
Berberine is an isoquinoline alkaloid isolated from herb plants, such as Cortex
phellodendri (Huangbai) and Rhizoma coptidis (Huanglian). Huanglian and Huangbai
have used as “heat-removing” agents. In addition, berberine has been reported to have
anti-inflammatory effects both in vivo and in vitro. Hypoxia is a major stimulator to
cause the pathogenesis of many diseases such as heart disease, neuron death,
cardiovascular diseases, and cancer. Tumors hypoxia has been indicated to be strongly
associated with tumor malignant progression, propagation, and resistance to therapy.
Therefore, hypoxia has become a central issue in tumor physiology and cancer
treatment. However, the effect of berberine on male reproduction in hypoxia condition
is still not known. The purpose of this study is to investigate the effect of berberine in
hypoxia condition on testosterone secretion from TM3 cells, a kind of rat Leydig cell
lines. In 12-well plate, TM3 cells (4×104 /ml) were incubated with berberine (10, 20,
50 g/ml) under normoxia (21% O2) or hypoxia (1% O2) for 1 hour and treated with
or without hCG (0.5 IU/ml) for 16 hours. Media were collected later, centrifuged, and
stored in –20℃ for testosterone EIA. Meanwhile, different activators/inhibitors of
signal transduction with berberine and hCG were added into the media. Stimulatory
effect of berberine on testosterone release from TM3 cells was observed under
hypoxia condition. Significant inhibitory effect of nifedipine (L-type calcium channel
blocker), U73122 (PLC inhibitor), and helenaline (NF-B inhibitor) were found in
TM3 cells under hypoxia condition. In contrast, AG490 (JAK-2 inhibitor), forskolin
(activator of adenylyl cyclase), SQ22536 (adenylyl cyclase inhibitor), and
GF109203X (PKC inhibitor) did not affect the testosterone secretion from TM3 cells
under hypoxia condition. Our results showed that, under hypoxia condition, the
stimulatory effect of berberine on testosterone secretion from Leydig TM3 cells
maybe mediated through phospholipase C, calcium channel, and NF-B pathways.
3
Introduction
Berberine is an isoquinoline alkaloid (Zhou and Mineshita, 2000) existed
in Hydrastis Canadensis (goldenseal), Cortex phellodendri (Huangbai), and
Rhizoma coptidis (Huanglian) (Ikram 1975). Extracts from these plant root or
skin are used for disease treatment, e.g. lumbago, rheumatism, and fever
(Yesilada and Kupeli 2002). Huanglian has been used as a herb in India and
China for more than 3000 years (Shirwaikar, Shirwaikar et al. 2006). As a herb,
huanglian has been employed as prophylactic drug, and for GI disorder (Lin,
Chung et al. 2005). Studies indicated that berberine poses the inhibitory effect
on cyclooxygenase-2 activity and lipoxygenase (Misik, et al., 1995),
interleukin-8 increase in inflammatory enteric disease (Nielsen, et al., 1987),
and colitis induced by trinitrobenzene sulfonic acid (Zhou and Mineshita,
2000). Also, the edema in hind paw in mice induced by serotonin can be
inhibited by berberine in vivo (Kupeli, et al., 2002). Moreover, studies showed
that berberine can be used in treatment hepatic injury (Hwang, et al., 2002),
thyroxine induced ventricular hypertrophy (Yang, et al., 2006),
hypercholesterolemia (Kong, et al., 2004), decreased bone mineral density (Wu,
et al., 1999; Li, et al., 2006), parasite infection (Subbaiah and Amin, 1967;
Stermitz, et al., 2000; Hawrelak J, 2003; Kong, et al., 2004),
erectile-dysfunction (Chiou, et al., 1998; Drewes, et al., 2003), tumor
metastasis (Hoshi, et al., 1976; Fukuda, et al., 1999; Marinova, et al., 2000;
Mitani, et al., 2001; Peng, et al., 2006; Yang, et al., 2006).
Studies showed that hypoxia decreased thyrotrophs and thyroid cells
(Gonsly, 1985), promoted glucocorticoid (Raff, et al., 2003) and erythropoietin
secretion (Wang, et al., 1996), inhibited aldosterone secretion (Raff, et al.,
1997;Raff and Bruder, 2006), disturbed the hypothalamic-pituitary-gonadal
function in male (Wang AC, 1990), lowered LH/FSH (Semple et al., 1981;
Farias et al., 2008) and testosterone secretion(Semple et al., 1984). Also,
Obstructive sleep apnea is considered to relate to intermittent hypoxia
condition. In these patients, low testosterone concentration is a common
syndrome (Santamaria, Prior, and Fleetham. 1988; Hu et al., 1998; Luboshitzky
et al., 2002; Gambineri, Pelusi, and Pasquali. 2003; Luboshitzky et al., 2003;
Luboshitzky et al., 2005; Zhuravlev et al., 2009). This hypogonadism has been
related to age and obesity (Gambineri, Pelusi, and Pasquali. 2003; Luboshitzky
et al., 2002; Luboshitzky et al., 2005). However, Coste et al. (2006) indicated
that there is no significant relationship between hypoxia and hypogonsdism. In
addition, our lab has demonstrated that hypoxia stimulated testosterone
secretion in Leydig TM3 cells (Hwang et al., 2007) and increased testosterone
secretion in TM3 cells was found in intermittent hypoxia (Hwang et al., 2009).
In the present study, mouse Leydig cells were used to investigate the
effects of berberine on (1) testosterone secretion, (2) signal transduction, and (3)
the involvement of basic regulatory pathways in regulation of HIF-1, VEGF,
and ERK1/2 expression under normoxia and hypoxia condition.
4
Materials and Methods
Antibodies and reagents. Human chorionic gonadotropin (hCG) and mouse VEGF were purchased
from Sigma (St. Louis, MO). PD-98059 was purchased from Tocris Cookson
(Westwoods Business, Park Ellisville, MO). Anti-VEGF (1:200 dilution),
anti-phospho (p)-extracellular signal-regulated kinases 1 and 2 (ERK1/2;
1:1,000 dilution), anti--actin (1:8,000 dilution), and
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:500 dilution)
were purchased from Santa Cruz (Watsonville, CA). The horseradish
peroxidaseconjugated IgG, goat anti-rabbit IgG (1:6,000 dilution), and goat
anti-mouse IgG (1:8,000 dilution) were purchased from ICN Pharmaceuticals
(Aurora, OH).
Cell culture. TM3 Leydig cells, a nontumorogenic cell line derived from mouse testis,
were obtained from the Culture Collection and Research Center (Food Industry
Research and Development Institute, Taiwan, Republic of China). This cell line
responds to LH by increasing testosterone production and secretion through
mechanisms similar to those encountered in freshly isolated cells. Cells were
cultured in 75-cm2 flasks (Falcon, Franklin Lakes, NJ) in a 1:1 mixture of
Ham’s F-12 and DMEM (Sigma) that contained 15 mM HEPES, 0.12%
NaHCO3 supplemented with 0.45% glucose, 5% horse serum, 2.5% FCS
(Kibbutz Beit, Haemek, Israel), and 100 IU/ml potassium penicillin G + 100
g/ml streptomycin sulfate (Sigma). Cells were cultured at 37°C in either a
humidified atmosphere of normoxic conditions (95% air-5% CO2) or in a
modular incubator chamber (Billups-Rothenberg, Del Mar, CA) and flushed
with hypoxic gas (95% N2-5% CO2).
ELISA of Testosterone Concentrations of testosterone in collected media were determined by
5
ELISA (Enzyme-linked Immunosorbent Assay). Briefly, 0.1 ml of capture
antibodies (R & D systems, Minneapolis, MN, USA) were coated on the
polystyrene microtiter plates (NUNC, U16 Maxisorp type, Rochester, NY, USA)
and incubated at room temperature overnight. The plates were blocked the next
day and then incubated for 1 h. Then, 0.1 ml standard/sample was added and
incubated for 2 h. After washing 3 times, 0.1 ml of detection antibody (R & D
systems) was applied for 2 h. One hundred micorliters streptavidin horseradish
peroxidase (R & D systems) and then 0.1 ml tetramethylbenzidine substrate
(Clinical Science Products Inc., Mansfield, MA, USA) followed this incubation.
The reaction was stopped using 2 N sulfuric acid and optical density (OD)
reading was taken at 450 nm (BioTek, Winooski, VT, USA). All samples were
run in duplicates. The results were expressed as concentration of testosterone
(pg/ml) read from standard curves. The detection range, sensitivity, the
intraassay and interassay coefficients of variation are:7.8-500 pg/ml, 6 pg,
4.4%, and 7.7%, respectively.
Effect of hypoxia on the expressions of ERK1/2. Mouse TM3 Leydig cells (106 cells/10 ml) were seeded in 10-cm dishes
and then incubated with or without hCG at 1 IU/ml for 1 or 16 h in a normoxic
or hypoxic condition. At the end of incubation, cytoplasmic proteins were
extracted from the cells and used to determine the expression of VEGF, HIF-1,
p-ERK1/2, and p-p38 through Western blot.
Statistical analysis.
The data were expressed as means ± SE. The treatment means were
tested for homogeneity using ANOVA, and the difference between specific
means was tested for significance using Duncan’s multiple-range test or
Student’s t-test (Steel & Torrie, 1960). A difference between two means was
considered to be statistically significant when the P value was <0.05.
6
Results
Effect of glycyrrhizin and berberine on testosterone secretion under
normoxia
Significant increases of testosterone were found in TM3 cells treated with
berberine (10~50 g/ml) or hCG (0.5 IU/ml) (Fig. 1).
Signal pathways in TM3 after berberine treatment
Increased testosterone secretion were found in TM3 cells treated AG490
(Fig 3), Nifedipine (Fig 4), SQ22536 (Fig 5), U73122 (Fig 6), GF109203X (Fig
7), Helenaline (Fig 8), and berberine.
No change in testosterone secretion was found in TM3 cells after forskolin
(Fig. 2). Also, these activators/inhibitors had no effect on testosterone secretion
from TM3 cells treated with berberine and hCG (Fig. 9).
Effect of berberine on testosterone from TM3 under hypoxia condition
Significant increase of hCG on testosterone secretion from TM3 under
hypoxia were found at 0.5 IU/ml (Fig. 10A) and 16 h (Fig. 10B). Increased
testosterone secretion were observed in TM3 treated with berberine (10-20
g/ml) only or with hCG (0.5 IU/ml) (Fig. 11A).
Signal pathway in TM3 after berberine treatment under hypoxia condition
No difference in testosterone concentration was found between berberine
only and berberine + forskolin (10-6
M) (Fig. 11B), AG490 (10-6
M) (Fig. 12A)
treatment under hypoxia condition. Decreased testosterone was observed in
TM3 with berberine + nifedipine (Fig. 12B), U73122 (Fig. 13B), helenaline
(Fig. 14B) compared to berberine treatment only in hypoxia. However,
increased testosterone was found in TM3 with berberine + SQ22536 compared
to berberine only (Fig. 13A). Decreased media testosterone was found only in
10 g/ml berberine + GF109203X compared to berberine only in hypoxia (Fig.
14A).
Effect of berberine on HIF-1, VEGF, and ERK1/2 expression in TM3 under
7
hypoxia condition
No difference was found in VEGF in expression in TM3 between
berberine only or with hCG under hypoxia condition (Fig. 15A).
Augmented HIF-1 expression was found in TM3 with berberine only. In
contrast, lower expression of HIF-1 was observed after berberine and
hCG treatment (Fig. 15B). Enhanced p-ERK1/2 expression was found in
TM3 with berberine only or berberine + hCG treatment (Fig. 16A). Also,
stimulated p-p38 expression with berberine only or berberine + hCG
treatment (Fig. 16B)
8
Discussion
In the present studies, we found that: (1) the stimulatory effect of berberine on
testosterone secretion from TM3 might be through calcium ion channel ,
adenylyl cyclase, phospholipase C, protein kinase C, and NF-B; (2) under
hypoxia condition, the stimulatory effect of berberine on TM3 cells is part
through adenylyl cyclase, protein kinase C, phospholipase C, NF-B, HIF-1,
ERK1/2, and p38.
Previous studies have indicated that regulation of MAPK is associated with the
action of berberine in tumors or cells. Berberine inhibits the expression of
inflammatory cytokines in ARPE-19 cells, a human retinal pigment epithelial
cell line, through down-reugulation of the ERK1/2, JNK, and p38 pathways
(Wang, et al., 2012). Yan et al. (2012) showed that berberine promotes recovery
of dextran sulfate sodium (DSS)-induced colitis and decreases proinflammatory
cytokine production through MAPK. Also, in human colonic carcinoma cells,
berberine reduces cAMP-induced chloride secretion, which is mediated by
stimulation of ERK1/2 and p-38 (Alzamora, et al., 2011). Berberine
hydrochloride attenuates LPS-induced COX-2 expression and p38 activation in
small intestinal mucosa cells (Feng, et al., 2011). In addition, through the
activation of ERK1/2 and p38, berberine chloride induced the anti-Leishmanial
activity in macrophages (Saha, et al., 2011). In lung tumor, administration ob
berberine inhibits cell cycle progression and tumorgenesis through Akt, CREB
and MAPK pathways (James, et al., 2011). Zhang, et al. (2011) demonstrated
berberine moderates glucose and lipid metabolism through the activation of
AMPK, p38, JNK and PPAR. In our study, we found that berberine, in
normoxia or hypoxia condition could regulate testosterone secretion from TM3
cells through the activation of either ERK1/2, JNK, or p38. This finding is in
agreement with these previous studies.
In conclusion, our results demonstrate (1) glycyrrhizin stimulated testosterone
9
secretion from TM3 cells at least in part through the adenylyl cyclase, JAK-2,
calcium ion channel, and protein kinase C; (2) the stimulatory effect of
berberine on testosterone secretion from TM3 is via calcium ion channel ,
adenylyl cyclase, phospholipase C, protein kinase C, and NF-B; (3) under
hypoxia condition, glycyrrhizin stimulates testosterone secretion from TM3
cells through JAK-2, calcium ion channel, HIF-1, and ERK1/2; (4) the
stimulatory effect of berberine on TM3 cells is part through adenylyl cyclase,
protein kinase C, phospholipase C, NF-B, HIF-1, ERK1/2, and p38.
10
Acknowledgments
This study was supported by the grant (CMRPD10041 and CMRPD10042) from
Chang-Gung Memorial Hospital, Taipei, Taiwan, ROC.
Declaration of interest
The authors report no conflicts of interest. The authors alone are responsible for the
content and writing of the article.
11
References
Akamatsu, H., Komura, J., Asada, Y., and Niwa, Y. Mechanism of anti-inflammatory
action of glycyrrhizin: effect on neutrophil functions including reactive oxygen
species generation. Planta Med 1991, 57:119-121.
Alzamora R, O'Mahony F, Ko WH, Yip TW, Carter D, Irnaten M, and Harvey BJ.
Berberine Reduces cAMP-Induced Chloride Secretion in T84 Human Colonic
Carcinoma Cells through Inhibition of Basolateral KCNQ1 Channels. Front
Physiol, 2011; 2: 33.
Armanini D, Bonanini G, and Palermo M. Reduction of testosterone in men by
Licorice. N Engl J Med 1999, 341:1158.
Armanini D, Lewicka S, Pratesi C, Scali M, Zennaro MC, Zovato S, Gottardo C,
Simoncini M, Spigariol A, and Zampollo V. Further studies on the mechanism of
the mineralocorticoid action of licorice in humans. J Endocrinol Invest.
1996,19:624-629.
Baba, M., and Shigeta, S. Antiviral activity of glycyrrhizin against varicella-zoster
virus in vitro. Antiviral Res 1987, 7:99-107.
Beverdam A, Wilhelm D, and Koopman P Molecular characterization of three gonad
cell lines. Cytogenet Genome Res 2003; 101: 242-249.
Chiou WF, Chen J, and Chen CF. Relaxation of corpus cavernosum and raised
intracavernous pressure by berberine in rabbit. Br J Pharmacol 1998, 125:
1677-1684.
Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK, and Do MS. Berberine
reduces the expression of adipogenic enzymes and inflammatory molecules of
3T3-L1 adipocyte. Exp Mol Med 2006, 38: 599-605.
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., and Doerr, H. W.
Glycyrrhizin, an active component of liquorice roots, and replication of
SARS-associated coronavirus. Lancet 2003, 361:2045-2046.
Coste O, Van Beers P, Charbuy H, Bogdan A, and Touitou Y. Simulation of
long-haul flights in humans: prolonged mild hypoxia does not alter the circadian
time structure of plasma testosterone and gonadotrophins. Steroids 2006, 71:
214–221.
Drewes SE, George J, and Khan F. Recent findings on natural products with
erectile-dysfunction activity. Phytochemistry 2003, 62: 1019-1025.
Farese RV Jr, Biglieri EG, Shackleton CHL, Irony I, and Gomez-Fontes R.
Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1223-
1227
Farias JG, Bustos-Obregon E, Tapia PJ, Gutierrez E, Zepeda A, Juantok C, Cruz G,
Soto G, Benites J, and Reyes JG. Time course of endocrine changes in the
hypophysis-gonad axis induced by hypobaric hypoxia in male rats. J Reprod
Dev 2008, 54: 18–21.
Feng AW, Yu C, Mao Q, Li N, Li QR, and Li JS. Berberine hydrochloride attenuates
cyclooxygenase-2 expression in rat small intestinal mucosa during acute
endotoxemia. Fitoterapia, 2011; 82(7): 976-982.
12
Finney, R. S., and Somers, G. F. The antiinflammatory activity of glycyrrhetinic acid
and derivatives. J Pharm Pharmacol 1958, 10:613-620.
Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, and Fujiwara H. Inhibition by
berberine of cyclooxygenase-2 transcriptional activity in human colon cancer
cells. J Ethnopharmacol 1999, 66: 227-233.
Fukui M, Kitagawa Y, Nakamura N, and Yoshikawa T. Glycyrrhizin and serum
testosterone concentrations in male patients with type 12 diabetes. Diabetes Care
2003, 26:2962.
Gambineri A, Pelusi C, and Pasquali R. Testosterone levels in obese male patients
with obstructive sleep apnea syndrome: relation to oxygen desaturation, body
weight, fat distribution and the metabolic parameters. J Endocrinol Invest 2003,
26: 493–498.
Gumpricht E, Dahl R, Devereaux MW, and Sokol RJ. Licorice Compounds
Glycyrrhizin and 18β-Glycyrrhetinic Acid Are Potent Modulators of Bile
Acid-induced Cytotoxicity in Rat Hepatocytes J. Biol. Chem., 2005; 280: 10556
- 10563.
Hattori, T., Ikematsu, S., Koito, A., Matsushita, S., Maeda, Y., Hada, M., Fujimaki, M.,
and Takatsuki, K. Preliminary evidence for inhibitory effect of glycyrrhizin on
HIV replication in patients with AIDS. Antiviral Res 1989, 11:255-261.
Hawrelak, J. Giardiasis: pathophysiology and management. Altern Med Rev 2003, 8:
129-142.
Hikino, H. [Antihepatotoxic activity of crude drugs]. Yakugaku Zasshi 1985,
105:109-118.
Hirabayashi, K., Iwata, S., Matsumoto, H., Mori, T., Shibata, S., Baba, M., Ito, M.,
Shigeta, S., Nakashima, H., and Yamamoto, N. Antiviral activities of
glycyrrhizin and its modified compounds against human immunodeficiency virus
type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1) in vitro. Chem Pharm
Bull (Tokyo) 1991, 39:112-115.
Hoshi A, Ikekawa T, Ikeda Y, Shirakawa S, and Iigo M. Antitumor activity of
berberrubine derivatives. Gann 1976, 67: 321-325.
Hwang GS, Chen ST, Chen TJ, and Wang SW*. Effects of hypoxia on testosterone
release in rat Leydig cells. Am J Physiol Endocrinol Metab, 2009; 297: E1039 -
E1045.
Hwang JM, Wang CJ, Chou FP, Tseng TH, Hsieh YS, Lin WL, and Chu CY.
Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative
damage in rat liver. Arch Toxicol 2002, 76: 664-670.
Hwang GS, Wang, SW*, Tseng, WM; Yu, CH, and Wang, PS*. Effect of Hypoxia on
the Release of Vascular Endothelial Growth Factor and Testosterone in Mouse
TM3 Leydig cells. Am J Physiol Endocrinol Metabol. 2007, 292:E1763-E1769.
Hu Y, Asano K, Mizuno K, Usuki S, and Kawakura Y. Comparisons of serum
testosterone and corticosterone between exercise training during normoxia and
hypobaric hypoxia in rats. Eur J Appl Physiol Occup Physiol 1998, 78:
417–421.
Iizuka N, Hazama S, Yoshimura K, Yoshino S, Tangoku A, Miyamoto K, Okita K, and
Oka M. Anticachectic effects of the natural herb Coptidis rhizoma and berberine
on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer 2002, 99:
286-291.
Ikram, M. (1975). A review on the chemical and pharmacological aspects of genus
Berberis. Planta Med 1975, 28: 353-8.
Imanishi, N., Kawai, H., Hayashi, Y., Yatsunami, K., and Ichikawa, A. Effects of
13
glycyrrhizin and glycyrrhetinic acid on dexamethasone-induced changes in
histamine synthesis of mouse mastocytoma P-815 cells and in histamine release
from rat peritoneal mast cells. Biochem Pharmacol 1989, 38:2521-2526.
Ishihara, M., Homma, M., Kuno, E., Watanabe, M., and Kohda, Y. [Combination use
of kampo-medicines and drugs affecting intestinal bacterial flora]. Yakugaku
Zasshi 2002, 122:695-701.
James MA, Fu H, Liu Y, Chen DR, and You M. Dietary administration of berberine or
Phellodendron amurense extract inhibits cell cycle progression and lung
tumorigenesis. Mol Carcinog, 2011; 50(1): 1-7.
Kodama T, Shimizu N, Yoshikawa N, Makino Y, Ouchida R, Okamoto K, Hisada T,
Nakamura H, Morimoto C, & Tanaka H. Role of the glucocorticoids receptor for
regulation of hypoxia-dependent gene expression. J Biol Chem 2003, 278:
33384-33391.
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S,
Wu J, Wang Y, Li Z, Liu J, and Jiang JD. Berberine is a novel
cholesterol-lowering drug working through a unique mechanism distinct from
statins. Nat Med 2004, 10: 1344-1351.
Kumagai, A., Nanaboshi, M., Asanuma, Y., Yagura, T., and Nishino, K. Effects of
glycyrrhizin on thymolytic and immunosuppressive action of cortisone.
Endocrinol Jpn 1967, 14:39-42.
Kumagai, A., Yano, S., Takeuchi, K., Nishino, K., Asanuma, Y., Nanaboshi, M., and
Yamamura, Y. An Inhibitory Effect of Glycyrrhizin on the Antigranulomatous
Action of Cortisone. Endocrinology 1964, 74:145-148.
Kupeli E, Kosar M, Yesilada E, Husnu K, and Baser C. A comparative study on the
anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline
alkaloids from the roots of Turkish Berberis species. Life Sci 2002, 72: 645-657.
Lee DU, Kang YJ, Park MK, Lee YS, Seo HG, Kim TS, Kim CH, and Chang KC.
Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II,
TNF-alpha, iNOS, and IL-12 production in LPS-stimulated macrophages. Life
Sci 2003, 73: 1401-1412.
Lee J, Jung E, Park J, Jung K, Park E, Kim J, Hong S, Park J, Park S, Lee S, and Park
D. Glycyrrhizin induces melanogenesis by elevating a cAMP level in b16
melanoma cells. J Invest Dermatol, 2005; 124(2): 405-411.
Lee, Y. M., Hirota, S., Jippo-Kanemoto, T., Kim, H. R., Shin, T. Y., Yeom, Y., Lee, K.
K., Kitamura, Y., Nomura, S., and Kim, H. M. Inhibition of histamine synthesis
by glycyrrhetinic acid in mast cells cocultured with Swiss 3T3 fibroblasts. Int
Arch Allergy Immunol 1996, 110:272-277.
Li XK, Motwani M, Tong W, Bornmann W, and Schwartz GK. Huanglian, A chinese
herbal extract, inhibits cell growth by suppressing the expression of cyclin B1
and inhibiting CDC2 kinase activity in human cancer cells." Mol Pharmacol
2000, 58: 1287-1293.
Liang KW, Ting CT, Yin SC, Chen YT, Lin SJ, Liao JK, and Hsu SL Berberine
suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular
smooth muscle cell regrowth after in vitro mechanical injury. Biochem
Pharmacol 2006, 71: 806-817.
Lin SS, Chung JG, Lin JP, Chuang JY, Chang WC, Wu JY, and Tyan YS. Berberine
inhibits arylamine N-acetyltransferase activity and gene expression in mouse
leukemia L 1210 cells. Phytomedicine 2005, 12: 351-358.
Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, and Lavie P.
Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J
14
Clin Endocrinol Metab 2002, 87: 3394–3398.
Luboshitzky R, Lavie L, Shen-Orr Z, and Herer P. Altered luteinizing hormone and
testosterone secretion in middle-aged obese men with obstructive sleep apnea.
Obes Res 2005, 13: 780–786.
Luboshitzky R, Lavie L, Shen-Orr Z, and Lavie P. Pituitary-gonadal function in men
with obstructive sleep apnea. The effect of continuous positive airways pressure
treatment. Neuro Endocrinol Lett 2003, 24: 463–467.
Marinova EK, Nikolova DB, Popova DN, Gallacher GB, and Ivanovska ND.
Suppression of experimental autoimmune tubulointerstitial nephritis in BALB/c
mice by berberine. Immunopharmacology 2000, 48: 9-16.
Martin C, Yu AY, Jiang BH, Davis L, Kimberly D, Hohimer AR, and Semenza GL
Cardiac hypertrophy in chronically anemic fetal sheep: increased vascularization
is associated with increased myocardial expression of vascular endothelial
growth factor and hypoxia-inducible factor 1. Am J Obstet Gynecol 1998, 178:
527-534.
Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, and Cinatl J.
Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected
cells and inhibits virus replication and pro-inflammatory gene expression. PLoS
One, 2011; 6(5): e19705.
Misik V, Bezakova L, Malekova L, and Kostalova D. Lipoxygenase inhibition and
antioxidant properties of protoberberine and aporphine alkaloids isolated from
Mahonia aquifolium. Planta Med 1995, 61: 372-373.
Mitani N, Murakami K, Yamaura T, Ikeda T, and Saiki I. Inhibitory effect of berberine
on the mediastinal lymph node metastasis produced by orthotopic implantation
of Lewis lung carcinoma. Cancer Lett 2001, 165: 35-42.
Nagai, T., Egashira, T., Kudo, Y., Yamanaka, Y., and Shimada, T. Attenuation of
dysfunction in the ischemia-reperfused liver by glycyrrhizin. Jpn J Pharmacol
1992, 58:209-218.
Nielsen OH, Bukhave K, Elmgreen J, and Ahnfelt-Ronne I Inhibition of
5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils
by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987, 32: 577-582.
Okimasu, E., Moromizato, Y., Watanabe, S., Sasaki, J., Shiraishi, N., Morimoto, Y. M.,
Miyahara, M., and Utsumi, K. Inhibition of phospholipase A2 and platelet
aggregation by glycyrrhizin, an antiinflammation drug. Acta Med Okayama 1983,
37:385-391.
Olukoga A, and Donaldson D. Liquorice and its health implications. J Roy Soc
Promot Health 2000, 120:83-89.
Paolini, M., Barillari, J., Broccoli, M., Pozzetti, L., Perocco, P., and Cantelli-Forti, G.
Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing
enzymes. Cancer Lett 1999, 145:35-42.
Park, H. Y., Park, S. H., Yoon, H. K., Han, M. J., and Kim, D. H. Anti-allergic activity
of 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide. Arch Pharm Res 2004,
27:57-60.
Peng PL, Hsieh YS, Wang CJ, Hsu JL, and Chou FP. Inhibitory effect of berberine on
the invasion of human lung cancer cells via decreased productions of
urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl
Pharmacol 2006, 214: 8-15.
Raff H, Jankowski BM, Goodfriend TL, Baker JE, and Papanek PE. Effect of
exposure to hypoxia from birth on aldosterone in rabbits: role of unesterified
fatty acids. Am J Physiol Regulatory Integrative Comp Physiol 1997; 272:
15
R1084. –R1087.
Raff H , Jacobson L, and Cullinan WE. Elevated corticosterone and inhibition of
ACTH responses to CRH and ether in the neonatal rat: effect of hypoxia
from birth. Am J Physiol Regulatory Integrative Comp Physiol 2003;
285:R1224-R1230.
Raff H, and Bruder ED. Steroidogenesis in human aldosterone-secreting adenomas
and adrenal hyperplasias: effects of hypoxia in vitro. Am J Physiol Endocrinol
Metab 2006, 290: E199–E203.
Saha BP, Bhattacharjee S, Sarkar, Manna A, Majumder S, and Chatterjee M.
Berberine chloride mediates its anti-leishmanial activity via differential
regulation of the mitogen activated protein kinase pathway in macrophages.
PLoS One, 2011; 6: e18467.
Sakamoto K, and Wakabayashi K. Inhibitory effect of glycyrrhetinic acid on
testosterone production in rat gonads. Endocrinol Jpn 1988, 35:333-342.
Santamaria JD, Prior JC, and Fleetham JA. Reversible reproductive dysfunction in
men with obstructive sleep apnoea. Clin Endocrinol (Oxf) 1988, 28:461–470.
Schrofelbauer B, Raffetseder J, Hauner M, Wolkerstorfer A, Ernst W, and Szolar OH.
Glycyrrhizin, the main active compound in liquorice, attenuates
pro-inflammatory responses by interfering with membrane-dependent receptor
signalling. Biochem J, 2009; 421(3): 473-482
Semple PA, Graham A, Malcolm Y, Beastall GH, and Watson WS. Hypoxia,
depression of testosterone, and impotence in pickwickian syndrome reversed by
weight reduction. Br Med J (Clin Res Ed) 1984, 289: 801–802.
Semple PD, Beastall GH, Watson WS, and Hume R. Hypothalamic-pituitary
dysfunction in respiratory hypoxia. Thorax 1981, 36: 605–609.
Shibata, S., Takahashi, K., Yano, S., Harada, M., Saito, H., Tamura, Y., Kumagai, A.,
Hirabayashi, K., Yamamoto, M., and Nagata, N. Chemical modification of
glycyrrhetinic acid in relation to the biological activities. Chem Pharm Bull
(Tokyo) 1987, 35:1910-1918.
Shirwaikar A, Shirwaikar A, Rajendran K, and Punitha IS. In vitro antioxidant studies
on the benzyl tetra isoquinoline alkaloid berberine. Biol Pharm Bull 2006, 29:
1906-1910.
Steel RD, & Torrie JH. Principles and Procedures of Statististics. McGraw-Hill, New
York, 1960.
Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, and Lewis K et al.. Synergy in a
medicinal plant: antimicrobial action of berberine potentiated by
5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA
2000, 97: 1433-1437.
Subbaiah, TV. and Amin AH. Effect of berberine sulphate on Entamoeba histolytica.
Nature 197, 215: 527-528.
Takeda, R., Morimoto, S., Uchida, K., Nakai, T., Miyamoto, M., Hashiba, T.,
Yoshimitsu, K., Kim, K. S., and Miwa, U. Prolonged pseudoaldosteronism
induced by glycyrrhizin. Endocrinol Jpn 1979, 26:541-547.
Takeuchi T, Nishii O, Okamura T, and Yaginuma T. Effect of paeoniflorin,
glycyrrhizin, and glycyrrhetic acid on ovarian androgen production. Am J Chin
Med 1991, 19:73-78.
Tu CT, Li J, Wang FP, Li L, Wang JY, and Jiang W. Glycyrrhizin regulates CD4(+)T
cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway.
Int Immunopharmacol, 2012; 14(4): 410-421.
Wang AC. [Changes in hypothalamic-pituitary-gonadal function in male patients with
16
acute attack of chronic cor pulmonale]. Zhonghua Jie He He Hu Xi Za Zhi 1990
13: 102–105,
Wang Q, Qi J, Hu R, Chen Y, Kijlstra A, and Yang P. Effect of Berberine on
Proinflammatory Cytokine Production by ARPE-19 Cells following Stimulation
with Tumor Necrosis Factor-α. Invest. Ophthalmol. Vis. Sci., 2012; 53: 2395 -
2402.
Wu HL, Hsu CY, Liu WH, and Yung BY (1999). Berberine-induced apoptosis of
human leukemia HL-60 cells is associated with down-regulation of
nucleophosmin/B23 and telomerase activity. Int J Cancer 81: 923-929.
Yan F, Wang L, Shi Y, Cao H, Liu L, Washington MK, Chaturvedi R, Israel DA, Cao
H, Wang B, Peek RM, Wilson KT, and Polk DB. Berberine promotes recovery
of colitis and inhibits inflammatory responses in colonic macrophages and
epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol,
2012; 302: G504 - G514.
Yang L, Wang HD, Lu DX, Wang YP, Qi RB, Li J, Li F, and Li CJ. Effects of neutral
sulfate berberine on LPS-induced cardiomyocyte TNF-alpha secretion,
abnormal calcium cycling, and cardiac dysfunction in rats. Acta Pharmacol Sin
2006; 27: 173-178
Yesilada, E. and E. Kupeli. Berberis crataegina DC. root exhibits potent
anti-inflammatory, analgesic and febrifuge effects in mice and rats. J
Ethnopharmacol, 2002; 79: 237-248.
Yu, Z., Ohtaki, Y., Kai, K., Sasano, T., Shimauchi, H., Yokochi, T., Takada, H.,
Sugawara, S., Kumagai, K., and Endo, Y. Critical roles of platelets in
lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible
strategy for acute respiratory distress syndrome. Int Immunopharmacol 2005,
5:571-580.
Zhuravlev VN, Frank MA, and Gomzhin AI. Sexual functions of men with
obstructive sleep apnoea syndrome and hypogonadism may improve upon
testosterone administration: a pilot study. Andrologia 2009, 41: 193–195.
Zhou, H. and S. Mineshita. The effect of berberine chloride on experimental colitis in
rats in vivo and in vitro. J. Pharmacol. Exp. Ther 2000, 294: 822-829
Zhang Q, Xiao X, Feng K, Wang T, Li W, Yuan T, Sun X, Sun Q, Xiang H, and Wang
H. Berberine Moderates Glucose and Lipid Metabolism through Multipathway
Mechanism.. Evid Based Complement Alternat Med, 2011; 2011:
17
TM3 cells
Tes
tost
ero
ne
(p
g/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG(0.5 IU/ml) - + - - - + + + (3 hrs)
Ber (g/ml) (1 hrs)- - 10 20 50 10 20 50
*** ** ***
#####
Figure 1. Effect of berberine on testosterone secretion from TM3 cells treated with or
without hCG (0.5 IU/ml) under normoxia condition.
TM3 cells
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml)
Forskoline (10-6
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + +
(1 hrs)
Figure 2. Effect of berberine on testosterone secretion from TM3 treated with or
without forskolin (10-6
M; adenylyl cyclase activator). n=4.
18
TM3 cells
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml
AG490 (10-6
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 3. Effect of berberine on testosterone secretion from TM3 treated with or
without AG490 (10-6
M; JAK-2 tyrosine kinase inhibitor). n=4.
TM3 cells
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml
Nifedipine (10-4
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure .4 Effect of berberine on testosterone secretion from TM3 treated with or
without nifedipine (10-4
M; L-type calcium channel inhibitor). n=4.
19
TM3 cellsT
esto
ster
on
e (p
g/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml
SQ22536 (10-5
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 5. Effect of berberine on testosterone secretion from TM3 treated with or
without SQ22536 (10-5
M; adenylyl cyclase inhibitor). n=4.
TM3 cells
Test
oste
rone
(pg/
ml)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml)
U73122 (10-4
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 6. Effect of berberine on testosterone secretion from TM3 treated with or
without U73122 (10-4
M; phocpholipase C inhibitor). n=4.
20
TM3 cells
Test
oste
rone
(pg/
ml)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml)
GF109203X (10-6
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 7. Effect of berberine on testosterone secretion from TM3 treated with or
without GF109203X (10-6
M; protein kinase C inhibitor). n=4.
TM3 cells
Tes
tost
eron
e (
pg/m
l)
0
200
400
600
800
1000
1200
1400
1600
hCG (0.5 IU/ml)
Ber ( g/ml)
Helenaline (10-6
M)
(3 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 8. Effect of berberine on testosterone secretion from TM3 treated with or
without helenaline (10-6
M; NF-B inhibitor). n=4.
21
TM3 cellsT
esto
ster
on
e (p
g/m
l)
0
200
400
600
800
1000
hCG (0.5 IU/ml)
Ber (50 g/ml)
Forskoline (10-6
M)
AG490 (10-6
M)
Nifedipine (10-4
M)
SQ22536 (10-5
M)
U73122 (10-4
M)
GF109203X (10-6
M)
Helenaline (10-6
M)
(3 hrs)
(1 hrs)
- + - + + + + + + + +
- - + + + + + + + + +- - - - + - - - - - -- - - - - + - - - - -
- - - - - - + - - - -- - - - - - - + - - -
- - - - - - - - + - -- - - - - - - - - + -- - - - - - - - - - +
Figure 9. Effect berberine (50 g/ml) on testosterone secretion from hCG-treated
TM3 cells with or without activators/inhibitors.
22
A.
TM3 cellsT
esto
ster
one
(pg/
ml)
0
2000
4000
6000
8000
10000
hCG(IU/ml) 0 0.1 0.2 0.5 1 2 (16hrs)
B.
TM3 cells
Tes
tost
eron
e (p
g/m
l)
0
1000
2000
3000
4000
5000
hCG 0.5 IU/ml 0 3 6 16 24 (hrs)
Figure 10. Effect of hCG on testosterone secretion from TM3 under hypoxia condition
in different dosage of hCG(A) and time course (B).
23
A.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
hCG(0.5IU/ml) - - - - + + + + (16h)
Ber(g/ml) 0 10 20 50 - 10 20 50 (1h)
B.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
hCG (0.5 IU/ml)
Ber (g/ml)
Forskolin (10-6
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 11. Effect of berberine on testosterone secretion from TM3 treated with hCG
(A) and forskolin (B) under hypoxia condition.
24
A.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
200
400
600
800
1000
1200
1400
hCG (0.5 IU/ml)
Ber (g/ml)
AG490 (10-6
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
B.
TM3 cellshypoxia
Tes
tost
ero
ne
(pg
/ml)
0
2000
4000
6000
8000
10000
hCG (0.5 IU/ml)
Ber (g/ml)
Nifedipine (10-4
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 12. Effect of berberine on testosterone secretion from TM3 treated with hCG
and (A) AG490 or (B) nifedipine under hypoxia condition.
25
A.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
5000
10000
15000
20000
25000
30000
35000
hCG (0.5 IU/ml)
Ber (g/ml)
SQ22536 (10-5
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
B.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
10000
20000
30000
40000
50000
60000
hCG (0.5 IU/ml)
Ber (g/ml)
U73122 (10-4
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 13. Effect of berberine on testosterone secretion from TM3 treated with hCG
and (A) SQ22536 or (B) U73122 under hypoxia condition.
26
A.
TM3 cellshypoxia
Tes
tost
erone
(pg/m
l)
0
5000
10000
15000
20000
hCG (0.5 IU/ml)
Ber (g/ml)
GF109203X (10-6
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
B.
TM3 cellshypoxia
Tes
tost
eron
e (p
g/m
l)
0
2000
4000
6000
8000
10000
12000
hCG (0.5 IU/ml)
Ber (g/ml)
Helenaline (10-6
M)
(16 hrs)
(1 hrs)
- + - - - - - -
0 0 10 20 50 10 20 50 - - - - - + + + (1 hrs)
Figure 14. Effect of berberine on testosterone secretion from TM3 treated with hCG
and (A) AG490 or (B) nifedipine under hypoxia condition.
27
A.
β-Actin
VEGF
43 KDa
55 KDa
TM3 cells
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
hCG 0.5 IU/ml - + - - - + + + (1 hrs)
20110930N=1
5 x 104/ml
pass. 4hypoxia
Ber (g/ml) (1 hrs)- - 10 20 50 10 20 50
VEGF
/ A
ctin
(flod
relat
ive t
o co
ntro
l)β-Actin
VEGF
43 KDa
55 KDa
TM3 cells
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
hCG 0.5 IU/ml - + - - - + + + (1 hrs)
20110930N=1
5 x 104/ml
pass. 4hypoxia
Ber (g/ml) (1 hrs)- - 10 20 50 10 20 50
VEGF
/ A
ctin
(flod
relat
ive t
o co
ntro
l)
B.
β-Actin
HIF-1α43 KDa
72 KDa
TM3 cells
0.0
0.5
1.0
1.5
2.0
2.5
hCG 0.5 IU/ml - + - - - + + + (1 hrs)
20110930
N=1
5 x 104/ml
pass. 4
hypoxia
Ber (g/ml) (1 hrs)- - 10 20 50 10 20 50
HIF
-1A
ctin
(fol
d re
lativ
e to
con
trol)
β-Actin
HIF-1α43 KDa
72 KDa
TM3 cells
0.0
0.5
1.0
1.5
2.0
2.5
hCG 0.5 IU/ml - + - - - + + + (1 hrs)
20110930
N=1
5 x 104/ml
pass. 4
hypoxia
Ber (g/ml) (1 hrs)- - 10 20 50 10 20 50
HIF
-1A
ctin
(fol
d re
lativ
e to
con
trol)
Figure 15. Effect of berberine on (A) VEGF and (B) HIF-1 expression in TM3
treated with hCG (0.5 IU/ml) under hypoxia condition.
28
A.
TM3+Ber+hCGHypoxia
ER
K1/
2 /
-act
in
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
ERK 1ERK 2
Ber(g/ml) - - 10 20 50 10 20 50 (1h)
hCG(0.5 IU/ml) - + - - - + + + (3h)
p-ERK1/2
β-actin
TM3+Ber+hCGHypoxia
ER
K1/
2 /
-act
in
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
ERK 1ERK 2
Ber(g/ml) - - 10 20 50 10 20 50 (1h)
hCG(0.5 IU/ml) - + - - - + + + (3h)
p-ERK1/2
β-actin
B.
0
1
2
3
4
5TM3+Ber+hCGHypoxia
p-P3
8 /
-acti
n
Ber(g/ml) - - 10 20 50 10 20 50 (1h)
hCG(0.5 IU/ml) - + - - - + + + (3h)
p-P38
β-actin
0
1
2
3
4
5TM3+Ber+hCGHypoxia
p-P3
8 /
-acti
n
Ber(g/ml) - - 10 20 50 10 20 50 (1h)
hCG(0.5 IU/ml) - + - - - + + + (3h)
p-P38
β-actin
Figure 16. Effect of berberine on (A) ERK and (B) p38 expression in TM3 treated
with hCG (0.5 IU/ml) under hypoxia condition.